Givastomig not checked

I-Mab Biopharma US Limited · TJ033721

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
How it’s given
“Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), durvalumab, chemotherapy”In the company’s words, NCT04900818 on ClinicalTrials.gov
Tested for
Solid Tumor (2 trials), Advanced Cancer (2 trials), Metastatic Cancer (2 trials), Gastric Cancer (2 trials), Gastroesophageal Junction Carcinoma (2 trials), Esophageal Adenocarcinoma (2 trials), PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Main trialPhase 2
“The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help the researchers to learn more about the safety of givastomig. The main questions it aims to answer are: * Does the addition of givastomig to standard therapy increase the amount of time that participants survive without progression of their cancer? * What toxicities do participants experience when taking givastomig? Participants may be able to take part in the study if they have unresectable…”In the company’s words, NCT07432295 on ClinicalTrials.gov
Other names
TJ033721

Other drugs for Solid Tumor

All 2439 drugs for Solid Tumor

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Mar 2030 Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Phase 1Recruiting Dec 2026 Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Givastomig

Following is part of Solo: you see every change to Givastomig the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in